Treatment	treatment	O	O	O	O
of	of	O	O	O	O
risperidone-induced	risperidone-induced	O	O	O	O
hyperprolactinemia	hyperprolactinemia	O	DISEASE	OTHERS	I
with	with	O	O	O	O
a	a	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
agonist	agonist	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
children	children	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Risperidone	risperidone	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
potent	potent	O	O	O	O
antagonist	antagonist	O	O	O	O
of	of	O	O	O	O
both	both	O	O	O	O
serotonergic	serotonergic	O	O	O	O
(	(	O	O	O	O
5HT2A	5ht2a	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
dopaminergic	dopaminergic	O	O	O	O
D2	d2	O	O	O	O
receptors	receptors	O	O	O	O
is	is	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
hyperprolactinemia	hyperprolactinemia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
adults	adults	O	O	O	O
and	and	O	O	O	O
children	children	O	O	O	O
.	.	O	O	O	O

Chronically	chronically	O	O	O	O
elevated	elevated	O	O	O	O
prolactin	prolactin	O	O	O	O
levels	levels	O	O	O	O
in	in	O	O	O	O
children	children	O	O	O	O
with	with	O	O	O	O
prolactinomas	prolactinomas	O	O	OTHERS	I
may	may	O	O	O	O
be	be	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
arrested	arrested	O	O	O	O
growth	growth	O	O	O	O
and	and	O	O	O	O
development	development	O	O	O	O
resulting	resulting	O	O	O	O
in	in	O	O	O	O
either	either	O	O	O	O
delayed	delayed	O	O	OTHERS	I
puberty	puberty	O	O	OTHERS	I
or	or	O	O	O	O
short	short	O	O	O	O
stature	stature	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
possibilities	possibilities	O	O	O	O
stress	stress	O	O	O	O
the	the	O	O	O	O
importance	importance	O	O	O	O
of	of	O	O	O	O
developing	developing	O	O	O	O
a	a	O	O	O	O
safe	safe	O	O	O	O
and	and	O	O	O	O
effective	effective	O	O	O	O
approach	approach	O	O	O	O
to	to	O	O	O	O
drug-induced	drug-induced	O	O	O	O
hyperprolactinemia	hyperprolactinemia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
youth	youth	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
the	the	O	O	O	O
successful	successful	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
risperidone-induced	risperidone-induced	O	O	O	O
hyperprolactinemia	hyperprolactinemia	O	DISEASE	OTHERS	I
with	with	O	O	O	O
cabergoline	cabergoline	O	O	OTHERS	I
in	in	O	O	O	O
youth	youth	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
We	we	O	O	O	O
undertook	undertook	O	O	O	O
a	a	O	O	O	O
retrospective	retrospective	O	O	O	O
case	case	O	O	O	O
review	review	O	O	O	O
of	of	O	O	O	O
four	four	O	O	O	O
children	children	O	O	O	O
with	with	O	O	O	O
risperidone-induced	risperidone-induced	O	O	O	O
hyperprolactinemia	hyperprolactinemia	O	DISEASE	OTHERS	I
treated	treated	O	O	O	O
with	with	O	O	O	O
cabergoline	cabergoline	O	O	OTHERS	I
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Four	four	O	O	O	O
males	males	O	O	O	O
(	(	O	O	O	O
age	age	O	O	O	O
6	6	O	O	O	O
-	-	O	O	O	O
11	11	O	O	O	O
years	years	O	O	O	O
)	)	O	O	O	O
with	with	O	O	O	O
Diagnostic	diagnostic	O	O	O	O
and	and	O	O	O	O
Statistical	statistical	O	O	O	O
Manual	manual	O	O	O	O
of	of	O	O	O	O
Mental	mental	O	DISEASE	OTHERS	I
Disorders	disorders	O	DISEASE	OTHERS	I
(	(	O	O	O	O
fourth	fourth	O	O	O	O
edition	edition	O	O	O	O
)	)	O	O	O	O
bipolar	bipolar	O	DISEASE	OTHERS	I
disorder	disorder	O	DISEASE	OTHERS	I
or	or	O	O	O	O
psychoses	psychoses	O	DISEASE	OTHERS	I
,	,	O	O	O	O
with	with	O	O	O	O
risperidone-induced	risperidone-induced	O	O	O	O
elevations	elevations	O	O	O	O
in	in	O	O	O	O
serum	serum	O	O	O	O
prolactin	prolactin	O	O	O	O
levels	levels	O	O	O	O
(	(	O	O	O	O
57.5	57.5	O	O	O	O
-	-	O	O	O	O
129	129	O	O	O	O
ng/mL	ng/ml	O	O	O	O
,	,	O	O	O	O
normal	normal	O	O	O	O
5	5	O	O	O	O
-	-	O	O	O	O
15	15	O	O	O	O
ng/mL	ng/ml	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
were	were	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
cabergoline	cabergoline	O	O	OTHERS	I
(	(	O	O	O	O
mean	mean	O	O	O	O
dose	dose	O	O	O	O
2.13	2.13	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
0.09	0.09	O	O	O	O
mg/week	mg/week	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

When	when	O	O	O	O
serum	serum	O	O	O	O
prolactin	prolactin	O	O	O	O
levels	levels	O	O	O	O
normalized	normalized	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
four	four	O	O	O	O
subjects	subjects	O	O	O	O
(	(	O	O	O	O
mean	mean	O	O	O	O
11.2	11.2	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
10.9	10.9	O	O	O	O
ng/mL	ng/ml	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
cabergoline	cabergoline	O	O	OTHERS	I
dose	dose	O	O	O	O
was	was	O	O	O	O
reduced	reduced	O	O	O	O
to	to	O	O	O	O
1	1	O	O	O	O
mg/week	mg/week	O	O	O	O
in	in	O	O	O	O
three	three	O	O	O	O
of	of	O	O	O	O
four	four	O	O	O	O
subjects	subjects	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
mean	mean	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
cabergoline	cabergoline	O	O	OTHERS	I
was	was	O	O	O	O
523.5	523.5	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
129.7	129.7	O	O	O	O
days	days	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
mean	mean	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
risperidone	risperidone	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
788.5	788.5	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
162.5	162.5	O	O	O	O
days	days	O	O	O	O
.	.	O	O	O	O

Cabergoline	cabergoline	O	O	OTHERS	I
was	was	O	O	O	O
well	well	O	O	O	O
tolerated	tolerated	O	O	O	O
without	without	O	O	O	O
adverse	adverse	O	O	O	O
effects	effects	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Cabergoline	cabergoline	O	O	OTHERS	I
may	may	O	O	O	O
be	be	O	O	O	O
useful	useful	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
risperidone-induced	risperidone-induced	O	O	O	O
hyperprolactinemia	hyperprolactinemia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
youth	youth	O	O	O	O
;	;	O	O	O	O
however	however	O	O	O	O
,	,	O	O	O	O
further	further	O	O	O	O
research	research	O	O	O	O
is	is	O	O	O	O
needed	needed	O	O	O	O
.	.	O	O	O	O

